| Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ... New England Journal of Medicine 373 (25), 2425-2437, 2015 | 1773 | 2015 |
| Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial G Salles, JF Seymour, F Offner, A López-Guillermo, D Belada, L Xerri, ... The Lancet 377 (9759), 42-51, 2011 | 1254 | 2011 |
| CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma R Marcus, K Imrie, A Belch, D Cunningham, E Flores, J Catalano, ... Blood 105 (4), 1417-1423, 2005 | 1248 | 2005 |
| Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma G Hess, R Herbrecht, J Romaguera, G Verhoef, M Crump, C Gisselbrecht, ... Journal of Clinical Oncology 27 (23), 3822-3829, 2009 | 765 | 2009 |
| Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma R Marcus, K Imrie, P Solal-Celigny, JV Catalano, A Dmoszynska, ... Journal of Clinical Oncology 26 (28), 4579-4586, 2008 | 763 | 2008 |
| Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma I Papandreou, NC Denko, M Olson, H Van Melckebeke, S Lust, A Tam, ... Blood, The Journal of the American Society of Hematology 117 (4), 1311-1314, 2011 | 536 | 2011 |
| Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study M Dreyling, W Jurczak, M Jerkeman, RS Silva, C Rusconi, M Trneny, ... The Lancet 387 (10020), 770-778, 2016 | 535 | 2016 |
| Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study JA Burger, PM Barr, T Robak, C Owen, P Ghia, A Tedeschi, O Bairey, ... Leukemia 34 (3), 787-798, 2020 | 512 | 2020 |
| Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study S Choquet, V Leblond, R Herbrecht, G Socié, AM Stoppa, ... Blood 107 (8), 3053-3057, 2006 | 501 | 2006 |
| Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label … P Hillmen, T Robak, A Janssens, KG Babu, J Kloczko, S Grosicki, ... The Lancet 385 (9980), 1873-1883, 2015 | 421 | 2015 |
| AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma JP Leonard, M Trneny, K Izutsu, NH Fowler, X Hong, J Zhu, H Zhang, ... Journal of clinical oncology 37 (14), 1188-1199, 2019 | 398 | 2019 |
| The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, ... Blood, The Journal of the American Society of Hematology 132 (23), 2446-2455, 2018 | 368 | 2018 |
| Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ... Nature medicine 28 (2), 325-332, 2022 | 360 | 2022 |
| An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome DW Denning, A Marinus, J Cohen, D Spence, R Herbrecht, L Pagano, ... Journal of Infection 37 (2), 173-180, 1998 | 335 | 1998 |
| Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial M Hutchings, F Morschhauser, G Iacoboni, C Carlo-Stella, FC Offner, ... Journal of Clinical Oncology 39 (18), 1959-1970, 2021 | 331 | 2021 |
| Glofitamab for relapsed or refractory diffuse large B-cell lymphoma MJ Dickinson, C Carlo-Stella, F Morschhauser, E Bachy, P Corradini, ... New England Journal of Medicine 387 (24), 2220-2231, 2022 | 311 | 2022 |
| Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial N Kalakonda, M Maerevoet, F Cavallo, G Follows, A Goy, JSP Vermaat, ... The Lancet Haematology 7 (7), e511-e522, 2020 | 293 | 2020 |
| Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia RJ Kreitman, C Dearden, PL Zinzani, J Delgado, L Karlin, T Robak, ... Leukemia 32 (8), 1768-1777, 2018 | 263 | 2018 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 255 | 2019 |
| Impact of previous aspergillosis on the outcome of bone marrow transplantation F Offner, C Cordonnier, P Ljungman, HG Prentice, D Engelhard, ... Reviews of Infectious Diseases 26 (5), 1098-1103, 1998 | 253 | 1998 |
